Raloxifene

BreastfeedingPediatric
  • TRADE NAME: Evista (Lilly)
  • INDICATIONS: Osteoporosis; reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer
  • CLASS: Selective estrogen receptor modulator (SERM)
  • HALF-LIFE: 27.7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Cholestyramine, Levothyroxine

PREGNANCY CATEGORY: X

INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE

See full prescribing information for complete boxed warning.

Our database has 32 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
RESPIRATORY
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top